Cover Image
市場調查報告書

CNS(中樞神經系統)治療藥市場上最新的開發趨勢

Recent Developments in the CNS Drug Market

出版商 BMI Research 商品編碼 290257
出版日期 內容資訊 英文 76 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
CNS(中樞神經系統)治療藥市場上最新的開發趨勢 Recent Developments in the CNS Drug Market
出版日期: 2013年10月29日 內容資訊: 英文 76 Pages
簡介

神經科學整體市值約為1,453億美元,由於CNS(中樞神經系統)市場構成其中大部分,該領域還有投資的空間。CNS疾病殘留龐大的未滿足需求,開發平台治療藥開發維持著穩定成長。

本報告提供全球CNS(中樞神經系統)治療藥市場及近幾年的開發趨勢相關資料、共同研究,也包含臨床實驗結果及新產品的認證調查、市場概要、主要企業簡介、主要8個治療領域現在的治療選項、開發平台等,為您概述為以下內容。

序文

摘要整理

CNS醫藥品市場

  • 市場概要
  • 主要企業
    • AstraZeneca
    • Biogen Idec
    • Eli Lilly
    • Endo Pharmaceuticals
    • Forest Laboratories
    • GlaxoSmithKline
    • Johnson & Johnson
    • Lundbeck
    • Otsuka
    • Pfizer
    • Purdue Pharma/Mundipharma/Napp Pharmaceuticals
    • Teva

CNS市場部門

  • 疼痛
    • 疼痛的種類
    • 目前疼痛的治療選項
    • 疼痛開發平台
  • 精神分裂症、躁鬱症
    • 目前治療選項
    • 開發平台
  • 憂鬱症
    • 目前治療選項
    • 開發平台
  • 注意力不足過動症(ADHD)
    • 目前治療選項
    • 開發平台
  • 癲癇
    • 目前治療選項
    • 開發平台
  • 多發性硬化症
    • 目前治療選項
    • 開發平台
  • 老年癡呆症
    • 目前治療選項
    • 開發平台
  • 帕金森氏症
    • 目前治療選項
    • 開發平台

參考資料

圖表清單

目錄
Product Code: RF215

This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical trial results and new product approvals across 8 key therapy areas.

Despite recent technological advances, relatively few novel treatments have been launched within the CNS market over the last decade. Many of the current market leaders are beginning to face generic competition or will do within the next five years.

However, the overall neuroscience market is worth approximately US$145.3 billion, and with the CNS market forming a large part of that, there is room for investment to be made. Significant unmet need remains for a number of CNS conditions and the pipeline of drug development remains strong.

This new report from Espicom reviews the recent developments in drug therapy for a number of CNS disorders, providing five-year sales for the current market leaders and forecasts for these and potential therapies to 2020, where available.

Key market questions answered by the report:

  • Who are the current leading players in the CNS drugs market?
  • What are the current treatment options for schizophrenia and bipolar disorder?
  • What are the recent FDA approvals for depression drugs?
  • Which new therapies will increase the value of the multiple sclerosis market?

The Recent Developments in the CNS Drugs Market report is the foolproof business resource for any industry executive that needs to fully understand the current and forecasted CNS market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers.

What this report contains:

  • Executive Summary
  • The CNS Drugs market overview including the 13 current leading players
  • CNS market sectors breakdown including current treatment options, sales and forecast figures and what's in the pipeline for the following therapy areas:
    • Pain
    • Schizophrenia and Bipolar Disorder
    • Depression
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Epilepsy
    • Multiple Sclerosis
    • Alzheimer's Disease
    • Parkinson's Disease

Table of Contents

Foreword 1

Executive Summary 3

The CNS Drugs Market 4

  • Market Overview 4
  • The Leading Players 6
    • AstraZeneca 8
    • Biogen Idec 8
    • Eli Lilly 8
    • Endo Pharmaceuticals 8
    • Forest Laboratories 9
    • GlaxoSmithKline 9
    • Johnson & Johnson 9
    • Lundbeck 10
    • Otsuka 10
    • Pfizer 10
    • Purdue Pharma/Mundipharma/Napp Pharmaceuticals 11
    • Shire 11
    • Teva 11

CNS Market Sectors 12

  • Pain 12
    • Types of Pain 12
      • Nociceptive Pain 12
      • Neuropathic Pain 12
      • Psychogenic Pain 13
    • Current Treatment Options for Pain 13
      • Pain Drug Sales and Forecasts 15
      • Neuropathic Pain Management 17
      • The World Health Organization's Pain Ladder 18
    • The Pain Pipeline 18
      • Pipeline Highlights and Recent Developments 21
        • Levadex (dihydroergotamine) 21
        • MoxDuo IR (morphine+oxycodone; Q8003) 22
        • MNK-795 (oxycodone+acetaminophen) 22
        • Posidur (SABER-Bupivacaine) 23
        • Remoxy (oxycodone) 23
        • Zohydro ER (hydrocodone bitartrate) 24
  • Schizophrenia and Bipolar Disorder 25
    • Current Treatment Options for Schizophrenia and Bipolar Disorder 25
      • Schizophrenia Drug Sales and Forecasts 26
    • The Schizophrenia and Bipolar Disorder Pipeline 28
      • Pipeline Highlights and Recent Developments 29
        • Aripiprazole 29
        • Cariprazine 29
        • Fanapt/Fanaptum (iloperidone) 30
  • Depression 31
    • Current Treatment Options for Depression 31
      • Depression Drug Sales and Forecasts 32
      • Recent FDA Approvals for Depression 34
        • Fetzima (levominacipram) 34
        • Brintellix (vortioxentine) 35
    • The Depression Pipeline 37
      • Pipeline Highlights and Recent Developments 38
        • Teva Scraps Nuvigil Development for Depression 38
        • BMS Terminates Development of BMS-820836 for Treatment-resistant Depression 38
  • Attention Deficit Hyperactivity Disorder (ADHD) 39
    • Current Treatment Options for ADHD 39
      • ADHD Drug Sales and Forecasts 40
    • The ADHD Pipeline 43
      • Pipeline Highlights and Recent Developments 43
        • Edivoxetine (LY2216684) 43
        • Metadoxine ER (MG01CI) 44
        • EB-1020 SR Phase IIa Pilot Study Initiated 44
        • Highland Raises Funds to Conduct Studies with Lead Compounds 45
        • Durect and Orient Select Lead Formulation for Oradur-ADHD Programme 45
  • Epilepsy 47
    • Current Treatments for Epilepsy 48
      • Epilepsy Drug Sales and Forecasts 49
    • The Epilepsy Pipeline 50
      • Pipeline Highlights and Recent Developments 51
        • Zebinix (eslicarbazepine) 51
        • Banzel/Inovelon (rufinamide) 52
        • Brivaracetam 52
  • Multiple Sclerosis 54
    • Relapsing Forms of Multiple Sclerosis 54
      • Primary and Secondary Progressive Multiple Sclerosis 54
    • Current Treatments for MS 55
      • Drug Sales and Forecasts 55
    • The MS Pipeline 59
      • Pipeline Highlights and Recent Developments 60
        • Plegridy (peginterferon beta-1a) 60
        • Relonsiv (interferon beta-1b) 60
        • S1P Receptor Agonists 61
        • Arbaclofen 61
        • Sativex for MS Spasticity 62
        • NEU2 Project in Support of Diagnostic for MS 62
  • Alzheimer's Disease 63
    • Current Treatments for AD 63
      • Alzheimer's Disease Drug Sales and Forecasts 63
    • The AD Pipeline 65
      • Pipeline Highlights and Recent Developments 68
        • Diagnosing AD with PET imaging 68
        • Lundbeck and Otsuka development agreement for Lu AE58054 68
        • Fixed-dose combination of memantine ER and donepezil (MDX-8704/ADS-8704) 69
        • Solanezumab 70
        • Gammagard (immunoglobulin) 70
        • Masitinib 71
        • BACE inhibitors 72
        • NNR modulators 73
  • Parkinson's Disease 74
    • Current Treatments for PD 74
      • Parkinson's Disease Drug Sales and Forecasts 75
    • The PD Pipeline 76
      • Pipeline Highlights and Recent Developments 77
        • Dopamine Precursor + DOPA Decarboxylase Inhibitor Combinations 77
        • Adenosine 2A Receptor Inhibition 77
        • Safinamide 78

Sources 80

List of Tables

  • Pain Therapies by Expected US Patent Expiry 13
  • Sales of Leading Pain Management Brands, 2008-2012 (US$ million) 16
  • Sales Forecast for Leading Pain Management Brands, 2014-2020 (US$ million) 17
  • Pain Clinical Pipeline 18
  • Schizophrenia and Bipolar Disorder Therapies by Excepted US Patent Expiry 25
  • Leading Schizophrenia and Bipolar Disorder Therapies by Sales, 2008-2012 (US$ million) 26
  • Sales Forecast for Leading Schizophrenia and Bipolar Disorder Brands, 2014-2020 (US$ million) 27
  • Schizophrenia and Bipolar Disorder Clinical Pipeline 28
  • Depression Therapies by US Patent Expiry 31
  • Leading Anti-depressant Brands by Sales, 2008-2012 (US$ million) 33
  • Sales Forecast for Leading Anti-Depressant Brands, 2014-2020 (US$ million) 33
  • Depression Clinical Pipeline 37
  • ADHD Therapies by US Patent Expiry 40
  • Leading ADHD Brands by Sales, 2008-2012 (US$ million) 41
  • Sales Forecast for Leading ADHD Brands, 2014-2020 (US$ million) 42
  • ADHD Clinical Pipeline 43
  • AEDs by Expected US Patent Expiry 48
  • Leading AEDs by Sales, 2008-2012 (US$ million) 49
  • Sales Forecast for Leading AEDs, 2014-2020 50
  • Epilepsy Clinical Pipeline 51
  • Approved Multiple Sclerosis Therapies 55
  • Multiple Sclerosis Leading Brands by Sales, 2008-2012 (US$ million) 57
  • Multiple Sclerosis Sales Forecast, 2014-2020 (US$ million) 58
  • Multiple Sclerosis Clinical Pipeline 59
  • Approved Alzheimer's Disease Therapies 63
  • Alzheimer's Disease Leading Brands by Sales, 2008-2012 (US$ million) 64
  • Alzheimer's Disease Sales Forecast for Leading Brands, 2014-2020 (US$ million) 65
  • Alzheimer's Disease Clinical Pipeline 67
  • Approved Parkinson's Disease Therapies 74
  • Parkinson's Disease Leading Brands by Sales, 2008-2012 (US$ million) 75
  • Parkinson's Disease Sales Forecast for Leading Brands, 2014-2020 (US$ million) 75
  • Parkinson's Disease Clinical Pipeline 76

List of Figures

  • CNS Market Value by Sector, 2008 (%) 5
  • CNS Market Value by Sector, 2012 (%) 6
  • Leading Companies by Reported CNS Drug Sales, 2012 (%) 7
  • Leading Companies by Forecast CNS Drug Sales, 2017 (%) 7
  • Sales Forecast for Top Five Anti-Depressant Brands, 2014-2020 (US$ million) 34
  • Sales Forecast for Selected ADHD Drugs, 2014-2020 (US$ million) 42
  • Epilepsy Drug Sales Forecast by Company, 2014-2020 (US$ million) 50
  • MS Drug Sales Forecast by Company, 2014-2020 (US$ million) 58
  • Alzheimer's Disease Forecast by Brand, 2014-2020 (US$ million) 65
  • Parkinson's Disease Forecast by Brand, 2014-2020 (US$ million) 76
Back to Top